A retrospective study of SBRT of metastases in patients with primary sarcoma.

We retrospectively reviewed the results of stereotactic body radiotherapy (SBRT) in 46 patients with a total of 136 metastases from primary sarcoma. The purpose of this study was to evaluate the overall response rate and side effects of SBRT in metastatic sarcoma. The patients were treated at Karolinska University Hospital between 1994 and 2005, using 3D conformal multifield technique and a stereotactic body-frame.

Undetectable late hepatic sequelae after hypofractionated stereotactic radiotherapy for liver tumors.

Hypofractionated liver stereotactic radiotherapy has produced long-term survival, but the hepatobiliary system is radiosensitive and may be severely damaged by the treatment. We have evaluated long-term radiation effects on hepatobiliary functions in the first long-term survivors reported after radiotherapy to the hepatobiliary system for liver tumors. Eleven patients were followed for up to 13 years after treatment of tumors≤9 cm in size.

Curative stereotactic body radiotherapy for liver malignancy.

Nine patients with 11 primary or secondary liver non-neuroendocrine malignancies with mean and maximum diameters of 4.0 and 7.7 cm became long-term survivors after precision irradiation in a stereotactic body frame.

A prospective Phase II trial of using extracranial stereotactic radiotherapy in primary and metastatic renal cell carcinoma.

A retrospective study has indicated that stereotactic radiotherapy (SRT) has a value in treating both primary tumors and singular metastatic lesions that cause local symptoms. Here we present the results of a prospective study evaluating the safety and local efficacy of SRT in metastatic or inoperable primary renal cancer. Thirty patients with metastatic renal cell carcinoma (RCC) or inoperable primary RCC received high-dose fraction SRT.

Detection of thymidylate synthase expression in lymph node metastases of colorectal cancer can improve the prognostic information.

Purpose: The level of thymidylate synthase (TS) in primary colorectal cancer (CRC) has been reported as a prognostic marker. The purpose of this study was to determine whether TS expression in lymph node metastases of Dukes' C CRC is a prognostic marker.

Patients And Methods: TS expression in the primary tumor and lymph node metastases from 348 patients with Dukes' C CRC was retrospectively assessed using immunohistochemistry and the monoclonal antibody TS 106.

Long-term results after fractionated radiation therapy for large brain arteriovenous malformations.

Objective: To study the results after fractionated radiotherapy of large arteriovenous malformations (AVMs).

Methods: Twenty-eight patients harboring large AVMs were treated between 1980 and 1985 with fractionated radiotherapy with up to 3.5 Gy per fraction twice a week to a total dose of 41 to 50 Gy.

Extracranial stereotactic radiotherapy for primary and metastatic renal cell carcinoma.

Background And Purpose: We investigated the results of using stereotactic radiotherapy (SRT) for 58 patients with renal cell carcinomas (RCC) who were evaluated restrospectively for response rates, local control rates and side effects.

Patients And Methods: From October 1997 to January 2003, 50 patients suffering from metastatic RCC and eight patients with inoperable primary RCC received high-dose fraction SRT while placed in a stereotactic body-frame. The most common dose/fractionation schedules used were 8 Gyx4, 10 Gyx4 and 15 Gyx3 during approximately 1 week.

Radiosurgery for recurring liver metastases after hepatectomy.

Background/aims: Most resected liver metastases from colorectal cancer recur. A minority of liver recurrences have been re-resected, but most re-resections fail and they decrease the postoperative performance status for a longer time than the initial resections, so that less demanding potentially curative treatments need evaluation.

Methodology: Four out of 5 liver-only recurrences after 18 consecutive liver resections were limited and suitable for radiosurgery.

Thymidylate synthase expression in rectal cancer and proliferation, assessed by cyclin A and Ki-67 expression.

Background: Levels of the enzyme thymidylate synthase (TS) are of prognostic significance in colorectal cancer. It may be argued that the levels of TS merely reflect the proliferative activity and could be replaced by markers of proliferation.

Materials And Methods: We used immunohistochemical approaches to examine the expression of TS, Cyclin A and Ki-67 in morphologically well-defined tumor areas in consecutive slices of rectal cancer, using the antibodies TS 106, NCL-Cyclin A and Mib-1.

Thymidylate synthase expression in colorectal cancer: a prognostic and predictive marker of benefit from adjuvant fluorouracil-based chemotherapy.

Purpose: We studied the prognostic value of thymidylate synthase (TS) expression in primary colorectal cancer (CRC) and the role of TS expression as a predictor of chemotherapeutic benefit in patients treated with adjuvant chemotherapy.

Patients And Methods: TS expression was immunohistochemically assessed on tumor sections from 862 patients with CRC Dukes' stages B and C enrolled onto randomized trials evaluating fluorouracil (5-FU)-based adjuvant chemotherapy.

Results: TS expression was an independent prognostic factor for disease-free (P =.